BMS-777607 CAS 1025720-94-8 Inhibitor Powder Dapagliflozin

BMS-777607 COA :


BMS-777607 Cas No : 1025720-94-8
Chemical Name    N-[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide
M .F :C25H19ClF2N4O4 
M.W :512.89
Solubility:  DMSO 47 mg/mL (91.63 mM) Water <1 mg/mL Ethanol <1 mg/mL
BMS-777607 is an inhibitor of Met-related for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases. 
In vivo 4% DMSO+30% PEG 300+ddH2O    5mg/mL
Preparation method :The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months.
BMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway..
Applications :In the highly metastatic murine KHT cells, treatment of BMS-777607 (~ 10 μM) for 2 hrs potently eliminated basal levels of autophosphorylated c-Met. BMS-777607 (25 mg/kg/day) decreased the number of KHT lung tumor nodules (28.3%), improved the morphological hemorrhage, and significantly impaired the metastatic phenotype, without apparent systemic toxicity. 
Notice : Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
Dosage form :10 ~ 25 mg/kg; p.o.; q.d.
BMS 777607 is a novel, selective and orally available ATP-competitive MET kinase inhibitor that primarily targets several MET family members, including RON, MET, Tyro-3 and AxI, with half maximal inhibitory concentration IC50 of 1.8 nmol/L, 3.9 nmol/L, 4.3 nmol/L and 1.1 nmol/L respectively. Moreover, at higher concentrations, BMS 777607 has been found to inhibit other protein tyrosine kinases, including Mer, Flt-3, Aurora B, Lck and VEGFR2 with IC50 of 14 nmol/L, 16 nmol/L, 78 nmol/L, 120 nmol/L and 180 nmol/L respectively. In previous studies, BMS 777607 potently inhibited the auto-phosphorylation of c-MET (IC50: 20 nmol/L) leading to impaired xenograft growth.





Relate Inhibitors Powder contact Bruce  BMS-777607 COA :


BMS-777607 Cas No : 1025720-94-8
Chemical Name    N-[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide
M .F :C25H19ClF2N4O4 
M.W :512.89
Solubility:  DMSO 47 mg/mL (91.63 mM) Water <1 mg/mL Ethanol <1 mg/mL
BMS-777607 is an inhibitor of Met-related for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases. 
In vivo 4% DMSO+30% PEG 300+ddH2O    5mg/mL
Preparation method :The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months.
BMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway..
Applications :In the highly metastatic murine KHT cells, treatment of BMS-777607 (~ 10 μM) for 2 hrs potently eliminated basal levels of autophosphorylated c-Met. BMS-777607 (25 mg/kg/day) decreased the number of KHT lung tumor nodules (28.3%), improved the morphological hemorrhage, and significantly impaired the metastatic phenotype, without apparent systemic toxicity. 
Notice : Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
Dosage form :10 ~ 25 mg/kg; p.o.; q.d.
BMS 777607 is a novel, selective and orally available ATP-competitive MET kinase inhibitor that primarily targets several MET family members, including RON, MET, Tyro-3 and AxI, with half maximal inhibitory concentration IC50 of 1.8 nmol/L, 3.9 nmol/L, 4.3 nmol/L and 1.1 nmol/L respectively. Moreover, at higher concentrations, BMS 777607 has been found to inhibit other protein tyrosine kinases, including Mer, Flt-3, Aurora B, Lck and VEGFR2 with IC50 of 14 nmol/L, 16 nmol/L, 78 nmol/L, 120 nmol/L and 180 nmol/L respectively. In previous studies, BMS 777607 potently inhibited the auto-phosphorylation of c-MET (IC50: 20 nmol/L) leading to impaired xenograft growth.





Relate Inhibitors Powder contact Bruce